OmnicellOMCL
About: Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
Employees: 3,590
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
501% more call options, than puts
Call options by funds: $10M | Put options by funds: $1.67M
55% more capital invested
Capital invested by funds: $1.28B [Q2] → $1.99B (+$707M) [Q3]
50% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 34
7% more funds holding
Funds holding: 240 [Q2] → 257 (+17) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3.73% less ownership
Funds ownership: 102.87% [Q2] → 99.14% (-3.73%) [Q3]
33% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 100
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
JP Morgan Anne Samuel 41% 1-year accuracy 14 / 34 met price target | 2%downside $44 | Neutral Maintained | 21 Nov 2024 |
Barclays Stephanie Davis 56% 1-year accuracy 9 / 16 met price target | 29%upside $58 | Equal-Weight Maintained | 31 Oct 2024 |
Craig-Hallum Matt Hewitt 52% 1-year accuracy 13 / 25 met price target | 42%upside $64 | Buy Maintained | 31 Oct 2024 |
B of A Securities Allen Lutz 73% 1-year accuracy 8 / 11 met price target | 27%upside $57 | Neutral Downgraded | 31 Oct 2024 |
Wells Fargo Stan Berenshteyn 57% 1-year accuracy 4 / 7 met price target | 9%downside $41 | Equal-Weight Maintained | 14 Oct 2024 |
Financial journalist opinion
Based on 11 articles about OMCL published over the past 30 days
